Login to Your Account


Auris gives 'ASSENT,' advances otoprotectant drug in hearing loss

By Jennifer Boggs
Managing Editor

Monday, June 20, 2016

As investors await top-line phase III data later this summer for AM-101, its lead program in tinnitus, Auris Medical Holding AG continued advancing its other late-stage candidate, AM-111, launching as planned a second phase III study in hearing loss. Both indications represent potential first-mover opportunities for the Swiss-based biopharma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription